Athenex Pharma Solutions, LLC, Clarence, NY

Is Athenex Pharma Solutions, LLC registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels its entry 503B, with FDA’s note “Out of business”.

Does Athenex Pharma Solutions, LLC hold a New York pharmacy license?

State pharmacy license records for New York are not checked: the Office of the Professions’ online verification search requires an access key and a check that the user is a person, and its bulk verification files are released only on request. This index reads only that state’s board actions. The Delaware Division of Professional Regulation also lists nonresident license AD-0000050 for Athenex Pharma Solutions, LLC, CLARENCE, NY, status Closed, as of Nov 10, 2026.

Has Athenex Pharma Solutions, LLC had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 untitled letter (Feb 13, 2019) and 1 FMD-145 letter (Aug 10, 2021) for Athenex Pharma Solutions, LLC. State board actions: record found. The New York State Education Department’s list of Board of Regents disciplinary actions against pharmacy establishments lists “Application for consent order granted Penalty agreed upon $20,000 fine, 1 year probation” dated Feb 11, 2019, case Cal. No. 30733 on registration 035379.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Athenex Pharma Solutions, LLC
Location
Clarence, NY
Type as FDA labels it
503B
FDA’s note
Out of business
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
2
Warning letters on FDA’s actions page
0
Latest action on that page
Sep 16, 2022
FDA Data Dashboard inspections
4 inspections: 3 VAI, 1 NAI; 3 published Form 483s
Form 483 text on this page
3 Form 483s, 6 observations
State board records
Not checked (license records); board actions matched: 1

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Athenex Pharma Solutions, LLC, a 503B facility, with 6 dated actions.

Document
Sep 16, 2022Form 483483 Issued 09/16/2022FDA copy (archived)
Aug 10, 2021FMD-145 letterFMD-145 Letter Issued 08/10/2021Not linked by FDA
Aug 28, 2019Form 483483 Issued 08/28/2019fda.gov
Aug 6, 2019Press release or statementFDA Statement : FDA Statement on Court Ruling Related to Compounded Bulk Drug Substances and the Agency’s Ongoing Efforts to Implement its Compounding Authorities (08/06/2019)FDA copy (archived)
Aug 2, 2019Press release or statementFirm Press Release : Athenex Provides an Update Regarding the Vasopressin Case (08/02/2019)FDA copy (archived)
Feb 13, 2019Untitled letterUntitled Letter Issued 02/13/2019FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Athenex Pharma Solutions, LLC, Clarence, NY (FEI number 3008876196), matched to this page by exact name, city and state. It lists 4 inspections: 3 VAI, 1 NAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Sep 16, 2022Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30088761961179659
Aug 28, 2019Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30088761961100698
Dec 13, 2017Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30088761961034742
Sep 3, 2014No Action Indicated (NAI)Drug Quality Assurance (Drugs)3008876196893756

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483s for this site have 6 numbered observations in all, across 3 inspections ending Dec 13, 2017 to Sep 16, 2022. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Sep 8, 2022 to Sep 16, 2022: 1 observation

Firm on the cover
Athenex Pharma Solutions, LLC, 11342 Main St, Clarence, NY 14031 -1718
FEI number
3008876196
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
158-15 Libert y Avenue Jamaica, NY 11433
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

There is a failure to thoroughly review the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.

Specifically, your investigations into sterility failures were not conducted thoroughly to evaluate potential root causes in the production facility and to implement robust corrective and preventative action plans to mitigate sterility risks to products. During Oct 2021 to Dec 2021, two sterility failures were observed on the finished product sterility testing, identified to be Gram Positive Rods (Bacillus licheniformis and Niallia circulans), belonging to Bacillus species of family. Sterility failures were investigated under #OOS-OOT-2021-0044 on 20Oct2021 for 8mg Norepinephrine in 0.9% Sodium Chloride (250mL IV Bag), Lot# <Redacted B4> and #OOS-OOT-2021-0054 on 02Dec2021 for 1 Unit/mL Vasopressin 0.9% Sodium Chloride (50mL), Lot <Redacted B4>. ...

Read the full 483 (PDF on fda.gov)

Inspection Aug 19, 2019: 1 observation

Firm on the cover
Athenex Pharma Solutions, LLC, 11342 Main St, Clarence, NY 1 4031 -1718
FEI number
3008876196
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
10 Waterview Blvd., 3rd Floor Parsippany, NJ 07054
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Written production and process control procedmes are not fo llowed in the execution of production and process control functions.

Specifically,

A. The firm's SOP No. APS-SOP-0344 "503B Bulle Formulation and Sealing Process" states to wipe down all work surfaces and equipment with a clean room wiped that has thoroughly wetted witb <Redacted B4>. However, on 08/20/2019 during the manufacturing of Norepinephrine lmg/ml, Lot# S1900185, an operator was obse1ved not wiping down all work smfaces and equipment with a clean room wipe that has been thoroughly wetted with <Redacted B4>

B. The firm's SOP No. APS-SOP-0308 "503B Syringe Compounding Aseptic Plj°cess" states to wipe the top seems around the raw syringe container with am (~) cloth. Wipe top of the container <Redacted B4> Wipe bottom of the container( <Redacted B4>making sure to get into crevices. Wipe all four sides of container <Redacted B4> Rotation of the container may be done for better angles to wipe. ...

Read the full 483 (PDF on fda.gov)

Inspection Dec 5, 2017 to Dec 13, 2017: 4 observations

Firm on the cover
Athenex Pharma Solutions, LLC, 11342 Main St C ITY, STATE, ZIP CODE, COUNTRY Clarence , NY 14031-1718
FEI number
3008876196
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
158-15 Liberty Avenue Jamaica, NY 11433
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the equipment to produce aseptic conditions.

Specifically,

On 12/6/ 17, an operator was observed disinfecting Bay <Redacted B4> ISO 5 <Redacted B4> Laminar Flow Hood <Redacted B4> with <Redacted B4> from <Redacted B4>, rather than <Redacted B4> , as outlined in the firm's procedure and performed in the firm's smoke studies. According to the firm's management and procedures, disinfection of the ISO 5 <Redacted B4> Laminar Flow Hood should be conducted by stating in the area <Redacted B4> in a manner that disinfects from the <Redacted B4>

Observation 2

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically,

On 12/6/17, I observed no environmental monitoring sampling being performed in the ISO 5 area, in Bay <Redacted B4> Laminar Flow Hood <Redacted B4> , where the operator is working, which is in front of the <Redacted B4> . Currently, the firm's media fill validations and environmental monitoring procedure state that <Redacted B4> however, viable monitoring is only performed in the <Redacted B4>

Observation 3

Equipment for adequate control over temperature is not provided when appropriate for the manufacture, processing, packing or holding of a drug product.

Specifically,

Your firrn 's monitored area is not where approved human finished drug products, which are used as the active ingredient in compounding operations, are stored. Currently, your firm only monitors the temperature in the warehouse in the <Redacted B4> however, approved human finished drug product (active ingredient) is located in the <Redacted B4> area of the warehouse across from the <Redacted B4> The firm has not conducted temperature mapping studies in the worst-case conditions, including Summer and Winter, for the current warehouse configuration. Your firm has only done a temperature mapping study in the Spring of the warehouse's current configuration, which showed a broader temperature range for the location where the raw material product is stored than where the temperature probes reside.

Observation 4

The labels of your outsourcing facility's drug products are deficient.

Specifically,

The labels of your outsourcing facility's drug products do not include information required by section 503B(a)(10)(A), including:

(a) The dosage form.

(b) A list of active and inactive ingredients, identified by established name and the quantity or proportion of each ingredient.

The following list contains examples of labels for drug products which do not contain the required information:

Epinephrine 2mg/250mL in 5% Dexirose

Epinephrine 4mg/250mL in 5% Dextrose

Phenylephrine 10mg/250mL in 0.9% Sodium Chloride

Phenylephrine 20mg/250mL in 0.9% Sodium Chloride

Phenylephrine 25mgl250mL in 0.9% Sodium Chloride

Phenylephrine 40mg/250mL in 0.9% Sodium Chloride

Phenylephrine 50mg/250mL in 0.9% Sodium Chloride

Norepinephrine 8mgl250mL in 0.9% Sodium Chloride

State board of pharmacy records

State pharmacy license records for New York are not checked: the Office of the Professions’ online verification search requires an access key and a check that the user is a person, and its bulk verification files are released only on request. This index reads only that state’s board actions. Board actions source.

Board actions

As the board words them, newest first. An entry that is a complaint, charge or notice the board filed is a charge, not a final decision; only an order or final action records the outcome.

What this covers: Board of Regents disciplinary actions against pharmacy establishments from the Office of the Professions’ summaries for the pharmacy profession, which start in 1994 (105 of 105 list pages read). These are final Regents actions, mostly consent orders; open complaints and charges not yet decided are not listed. Actions against individual pharmacists are not copied. New York pharmacy licenses and registrations are not checked. Actions in the data are dated Jan 14, 1994 to May 19, 2026.

Nonresident licenses in other states

These boards list a nonresident license whose record names this pharmacy’s own name, city and state.

Delaware Division of Professional Regulation, file dated Nov 10, 2026 (Delaware).

LicenseType as the board gives itName on the board recordLocationStatus
AD-0000050Outsourcing Facility-DistributorAthenex Pharma Solutions, LLCCLARENCE, NYClosed

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.